Influence of a priori information, designs, and undetectable data on individual parameters estimation and prediction of hepatitis c treatment outcome

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 7, 2013, Pages

  Nguyen, T H T ^a,b   Guedj, J ^a,b   Yu, J ^c   Levi, M ^d   Mentre F ^a,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAYES THEOREM; HEPATITIS C; KINETICS; LIMIT OF DETECTION; MEDICAL INFORMATION; NONHUMAN; PRIORITY JOURNAL; SIMULATION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 84881125383     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.31     Document Type: Article

References (40)

1. World Health Organization. Hepatitis C. Fact sheet No. 164., (Revised July 2012).
2. Maylin, S. et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135, 821-829 (2008).
3. Mangia, A., Mottola, L. & Piazzolla, V. Update on the treatment of patients with nongenotype 1 hepatitis C virus infection. Clin. Infect. Dis. 56, 1294-1300 (2013).
4. Manns, M.P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001). (Pubitemid 32913521)
5. Zeuzem, S. et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or J. Hepatol. 40, 993-999 (2004). (Pubitemid 38670134)
6. von Wagner, M. et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129, 522-527 (2005). (Pubitemid 41096640)
7. Bacon, B.R. et al.; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
8. Flamm, S.L. et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin. Gastroenterol. Hepatol. 11, 81-87. e4; quiz e5 (2013).
9. Kwo, P.Y. et al.; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705-716 (2010).
10. McHutchison, J.G. et al.; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009).
11. McHutchison, J.G. et al.; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292-1303 (2010).
12. Poordad, F. et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011).
13. Zeuzem, S. et al.; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428 (2011).
14. Lenz, O. et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J. Hepatol. 58, 445-451 (2013).
15. Mangia, A. & Mottola, L. Treatment of non-genotype 1 hepatitis C virus patients. Curr. Gastroenterol. Rep. 14, 87-93 (2012).
16. Reiser, M. et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41, 832-835 (2005). (Pubitemid 40462946)
17. Wartelle-Bladou, C., Le Folgoc, G., Bourliére, M. & Lecomte, L. Hepatitis C therapy in nongenotype 1 patients: the near future. J. Viral Hepat. 19, 525-536 (2012).
18. Gane, E.J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34-44 (2013).
19. Fried, M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36, S237-S244 (2002). (Pubitemid 35253486)
20. Mihm, U., Herrmann, E., Sarrazin, C. & Zeuzem, S. Review article: predicting response in hepatitis C virus therapy. Aliment. Pharmacol. Ther. 23, 1043-1054 (2006). (Pubitemid 43779343)
21. Arends, J.E. et al. Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy. J. Viral Hepat. 16, 867-875 (2009).
22. Snoeck, E. et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin. Pharmacol. Ther. 87, 706-713 (2010).
23. Williams, P.J. & Ette, E.I. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'. Clin. Pharmacokinet. 39, 385-395 (2000). (Pubitemid 32099467)
24. Rousseau, A. & Marquet, P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam. Clin. Pharmacol. 16, 253-262 (2002). (Pubitemid 35205335)
25. Guedj, J., Bazzoli, C., Neumann, A.U. & Mentré, F. Design evaluation and optimization for models of hepatitis C viral dynamics. Stat. Med. 30, 1045-1056 (2011).
26. Bergstrand, M. & Karlsson, M.O. Handling data below the limit of quantification in mixed effect models. AAPS J.11, 371-380 (2009).
27. Samson, A., Lavielle, M. & Mentré, F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput. Stat. Data. An. 51, 1562-1574 (2006). (Pubitemid 44709222)
28. Thiébaut, R. et al. Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med. Res. Methodol. 6, 38 (2006).
29. Yang, S. & Roger, J. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data. Pharm. Stat. 9, 313-330 (2010).
30. Mentré, F. et al. Current use and developments needed for optimal design in pharmacometrics: a study performed amongst DDMoRe's EFPIA members. CPT Pharmacometrics Syst. Pharmacol. 2, e46 (2013).
31. Dumont, C., Mentré, F., Gaynor, C., Brendel, K., Gesson, C. & Chenel, M. Optimal sampling times for a drug and its metabolite using SIMCYP() simulations as prior information. Clin. Pharmacokinet. 52, 43-57 (2013).
32. Vong, C., Ueckert, S., Nyberg, J. & Hooker, A.C. Handling below limit of quantification data in optimal trial design. Annual Meeting of the Population Approach Group in Europe. 2012. Abstract 2578 .
33. Combes, F., Retout, S., Frey, N. & Mentré, F. Prediction of shrinkage of individual parameters using the Bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics. Pharm. Res. doi:10.1007/s11095-013-1079-3.
34. Merlé, Y. & Mentré, F. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J. Pharmacokinet. Biopharm. 23, 101-125 (1995).
35. Chatterjee, A., Guedj, J. & Perelson, A.S. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir. Ther. (Lond.) 17, 1171-1182 (2012).
36. Dahari, H., Ribeiro, R.M. & Perelson, A.S. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46, 16-21 (2007). (Pubitemid 47171916)
37. Dahari, H., Lo, A., Ribeiro, R.M. & Perelson, A.S. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J. Theor. Biol. 247, 371-381 (2007). (Pubitemid 46863436)
38. Wu, H., Zhu, H., Miao, H. & Perelson, A.S. Parameter identifiability and estimation of HIV/ AIDS dynamic models. Bull. Math. Biol. 70, 785-799 (2008).
39. Bochud, P.Y. et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J. Hepatol. 55, 980-988 (2011).
40. Dahari, H., Shudo, E., Cotler, S.J., Layden, T.J. & Perelson, A.S. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir. Ther. (Lond.) 14, 459-464 (2009).